IN8bio, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| IN8bio, Inc. | INAB - NASDAQ |
$10.00-$12.00 | $10.00 | $10.00 | 4 million | 7/30/2021 |
| B. Riley Securities | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): 1st Filed 2020-10-16 Terms Added 2020-11-05 Filed 2021-03-31 Underwriters Amended 2021-07-20 Terms Added 2021-07-22 | ||||||
IN8bio, Inc. Quote & Chart - Click for current quote - INAB
IPO Boutique aggregates information on public companies and private companies, such as "INAB" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About IN8bio, Inc. (adapted from IN8bio, Inc. prospectus):
They are a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "INAB" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.